Medical Condition News

RSS

Provectus announces final data from PV-10 Phase 2 trial on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that Phase 2 final data on PV-10 for metastatic melanoma will be presented at the 2nd European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

9 May 2012

Probiotics may reduce the risk of antibiotic associated diarrhoea

Probiotics are live microorganisms intended to boost health, such as the bacteria in some yogurts. These are popular among the health conscious. One of probiotics' most popular uses is in preventing and treating digestive problems.

9 May 2012

C3BS’s C-Cath Injection Catheter receives CE Marking

The Belgian biotechnology company, Cardio3--BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces that it has received CE Marking for its intra-myocardial C-Cath Injection Catheter.

9 May 2012

One in six cancer cases worldwide related to preventable or curable infections

New research shows that one in six cancers - amounting to two million a year globally - are caused by largely treatable or preventable infections.

9 May 2012

CKD-EPI equation may provide more accurate risk prediction of death, ESRD

Kamyar Kalantar-Zadeh, M.D., M.P.H., Ph.D., principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), is the author of an invited editorial in JAMA. The editorial accompanied a study that included data from more than 1 million adults, and indicated the use of a newer risk prediction equation that classified fewer individuals as having chronic kidney disease and more accurately categorized the risk for death and end-stage renal disease.

9 May 2012

Botanical formula inhibits breast to lung cancer metastasis in mice

Scientists at Indiana University Health's Cancer Research Laboratory have found that a sophisticated botanical formula slows human breast cancer growth and inhibits breast to lung metastasis in mice. The formula contains extracts from medicinal mushrooms, medicinal herbs and purified nutritional compounds, and showed no toxic side-effects.

9 May 2012

Grade 12 researcher wins top honors at 2012 Sanofi BioGENEius Challenge Canada

An Ontario girl, 16, who invented a disease-fighting, anti-aging compound using nano-particles from trees, won top national honours today in the 2012 Sanofi BioGENEius Challenge Canada.

9 May 2012

Sildenafil may improve cardiac function in children, young adults with single ventricle defects

Sildenafil, also known as the erectile dysfunction drug Viagra, may give a boost to underdeveloped hearts in children and young adults with congenital heart defects. Researchers from The Children's Hospital of Philadelphia report that sildenafil significantly improved echocardiographic measures of heart function in children and young adult survivors of single ventricle heart disease palliation.

9 May 2012

Report notes rise in obesity slowing, but still huge health, cost problem

The obesity rate may rise to 42 percent from about a third of the U.S. population by 2030 if nothing changes, according to a report. Preventing that increase may save about $550 billion in medical costs over the next 20 years, Eric Finkelstein, the study author and an associate research professor at Duke University, said during a press briefing.

9 May 2012

Study shows effects of psychotropic drug treatment on brain morphology

It is increasingly recognized that chronic psychotropic drug treatment may lead to structural remodeling of the brain. Indeed, clinical studies in humans present an intriguing picture: antipsychotics, used for the treatment of schizophrenia and psychosis, may contribute to cortical gray matter loss in patients, whereas lithium, used for the treatment of bipolar disorder and mania, may preserve gray matter in patients.

9 May 2012

Highlights of orthopaedic research studies in JBJS

Below are highlights of orthopaedic research studies appearing in the May 2, 2012 issue of the Journal of Bone and Joint Surgery (JBJS), as well as the issue's full Table of Contents.

9 May 2012

UMD researchers design molecular container that can increase solubility of drugs

A cross-disciplinary team of researchers at the University of Maryland has designed a molecular container that can hold drug molecules and increase their solubility, in one case up to nearly 3000 times. Their discovery opens the possibility of rehabilitating drug candidates that were insufficiently soluble. It also offers an opportunity to improve successful drugs that could be made even better with better solubility.

9 May 2012

Researchers develop potent new drug that can kill tumor cells

All cells have the ability to recycle unwanted or damaged proteins and reuse the building blocks as food. But cancer cells have ramped up the system, called autophagy, and rely on it to escape damage in the face of chemotherapy and other treatments. Now, researchers at the Perelman School of Medicine; the Abramson Cancer Center; and the School of Arts and Sciences, at the University of Pennsylvania, have developed a potent new drug that clogs up the recycling machinery and kills tumor cells in mouse models.

9 May 2012

Non-drug therapy with NeuroStar TMS improves depression symptoms and QOL

New data released today at the annual meeting of the American Psychiatric Association show that patients with unipolar, non-psychotic Major Depressive Disorder (MDD) receiving transcranial magnetic stimulation (TMS) with NeuroStar TMS Therapy achieved significant improvements in both depression symptoms and in quality of life measurements.

9 May 2012

Current anticoagulant therapy to prevent stroke might not be sufficient for older women with AF

In a study that examined use of the anticoagulant medication warfarin and risk of stroke following a diagnosis of atrial fibrillation in older patients, women, especially those 75 years or older, had a higher risk of stroke than men, regardless of their risk profile and use of warfarin, suggesting that current anticoagulant therapy to prevent stroke might not be sufficient for older women, according to a study in the May 9 issue of JAMA.

9 May 2012

AARDA's Autoimmune Walk campaign surpasses first $20,000 fundraising milestone

Just a month after announcing its first-ever national "Autoimmune Walk: Linking Together for a Cure" campaign, American Autoimmune Related Diseases Association (AARDA) announced today that it has surpassed its first $20,000 fundraising milestone.

9 May 2012

New clue to predicting pre-eclampsia, the most common and severe pregnancy-related disease

An indication of whether a mother will develop pre-eclampsia, the most common and severe pregnancy-related disease, has been identified by a University of Sydney study.

9 May 2012

Higher levels of income inequality in the U.S. lead to more deaths

A new study provides the best evidence to date that higher levels of income inequality in the United States actually lead to more deaths in the country over a period of years.

9 May 2012

Rutin may inhibit formation of blood clots

A compound called rutin, commonly found in fruits and vegetables and sold over the counter as a dietary supplement, has been shown to inhibit the formation of blood clots in an animal model of thrombosis.

9 May 2012

Regulatory T cell diversity provides cumulative protective effect against RA

Untangling the root cause of rheumatoid arthritis has been a difficult task for immunologists, as decades of research has pointed to multiple culprits in our immune system, with contradictory lines of evidence. Now, researchers at The Wistar Institute announce that it takes a diverse array of regulatory T cells (a specialized subset of white blood cells) to prevent the immune system from generating the tissue-specific inflammation that is a hallmark of the disease. Regulatory T cell diversity, the researchers say, provides a cumulative protective effect against rheumatoid arthritis. When that diversity is not present, it allows the immune system to attack joints.

9 May 2012